Raymond James Starts Neogenomics (NEO) at Outperform
- Wall St. gains across sectors ahead of Trump inauguration
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Herbalife (HLF) Says SEC Requested Documents on Anti-Corruption Compliance in China; Reviewed with DoJ
- Investment Focus: History suggests Trump month will be stocks down, dollar up
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Raymond James initiated coverage on Neogenomics (NASDAQ: NEO) with an Outperform rating and a price target of $10.00.
Shares of Neogenomics closed at $8.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Ladenburg Thalmann Starts TC Pipelines (TCP) at Neutral
- Wedbush Assumes PayPal (PYPL) at Outperform
- UPDATE: Stifel Starts Safe Bulkers (SB) at Hold
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesRaymond James
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!